Biotech entity
pharma is the sole category represented across all 1 tracked stories. Verbund is most often covered alongside Johnson & Johnson, which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 3.3 across the same-window beat baseline.
Last mentioned: Mar 17, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Verbund is most often covered alongside Johnson & Johnson, which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 3.3 across the same-window beat baseline. At 5, the average consequence score sits below the same-window beat average of 6.3. We currently track 1 Biotech story that mention Verbund, all published on March 17, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Verbund. Shared-story counts are live from our verified record — not editorial picks.
Quarterly Earnings
Expected announcement of financial results and pipeline updates for PTGX and OEZVY.
JNJ-2113 Phase 3 Progress
Johnson & Johnson advances oral peptide JNJ-2113 into pivotal trials.
Takeda Partnership
Protagonist signs a global licensing agreement for rusfertide with $300M upfront.
Protagonist Therapeutics (PTGX) is set to report quarterly earnings this Wednesday, with investors focused on the commercial trajectory of its Takeda-partnered rusfertide. The results come at a critical juncture as the company transitions from a clinical-stage R&D house to a commercially-oriented biotech entity.
Verbund is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
